Article Abstract

Single agent anti PD-1 inhibitors in esophageal cancer—a first step in a new therapeutic direction

Authors: Elaine M. Walsh, Ronan J. Kelly


Esophageal squamous cell carcinomas and adenocarcinomas have proven to be inherently resistant to systemic treatments as a result of histological, molecular and etiological heterogeneity, with limited responses seen after first line therapy. The promise of immunotherapy in esophagogastric cancer has been suggested for a long time due to the recognized link between infection, chronic inflammation, and malignancy.